We support the translation of innovation into pharmacological concepts and therapies. We believe that the most innovative therapeutic ideas deserve the best development tools. We use Systems Pharmacology as a key tool to maximize the success of your preclinical program, clinical study or registration.
News
New poster on the prediction of an antibody's half-life in human from preclinical data at the Basel Festival of Biologics (10-12 October 2023)
11 October, 2023
New publication with the contribution of LYO-X on the better aligned Alzheimer's Q-ATN model
17 July, 2023
Joint LYO-X/ ETH D-BSSE Block Course on Modeling and Simulation in Drug Development
11 September, 2023
LYO-X will be recruiting at the Forum EPFL 2022
3 October, 2022
Curious to learn more about LYO-X AG? Then join us at the Forum EPFL at the Swisstech Convention Center in Lausanne:
Keep an eye on your target - Why increasing the half-life of your antibody is not always the solution.
22 June, 2021
LYO-X is a consulting and modeling & simulation company specialized in PK/PD and Quantitative Systems Pharmacology for the preclinical, translational and clinical development of biologics and novel drug formats.
Antibodies
Bi-specifics
ADC's
Nanobodies
Fab Fragments
Cell
Based Therapies
Based Therapies
PEGylated proteins
Oligonucleotides
Mission
Services
Our services includes consultancy and implementation of systems pharmacology and PK/PD modelling for target assessment, format selection, compound design, candidate selection, design and analysis of preclinical PK/PD and GLP toxicology studies, first in human dose selection, paediatric dose selection and dose / regimen finding studies.
Why Choose us
Our methods have been successfully applied in global pharmaceutical companies with tangible results including patents. We have the unique tested expertise developing bi-specifics, antibody-drug conjugates, scFv’s, nanobodies, cell based therapies to provide tailored support for your program.
Partners
LYO-X is closely working with KinDyn Consulting and Integrated Biologix in order to provide fully integrated consultancy for preclinical and clinical development of biologics covering toxicology, pathology, CMC, bioanalysis, PK/PD, immunogenicity and regulatory strategies.
LYO-X is partnering with Lixoft to provide you access to Monolix, the scientifically and technologically most advanced software for preclinical and clinical data analysis.
News
New poster on the prediction of an antibody's half-life in human from preclinical data at the Basel Festival of Biologics (10-12 October 2023)
11 October, 2023
New publication with the contribution of LYO-X on the better aligned Alzheimer's Q-ATN model
17 July, 2023
Joint LYO-X/ ETH D-BSSE Block Course on Modeling and Simulation in Drug Development
11 September, 2023
LYO-X will be recruiting at the Forum EPFL 2022
3 October, 2022
Curious to learn more about LYO-X AG? Then join us at the Forum EPFL at the Swisstech Convention Center in Lausanne:
Keep an eye on your target - Why increasing the half-life of your antibody is not always the solution.
22 June, 2021
This content is hosted by a third party. By showing the external content you accept the terms and conditions of vimeo.com.
Systems Pharmacology An Industry Perspective
This content is hosted by a third party. By showing the external content you accept the terms and conditions of vimeo.com.
Matthias Machacek - Systems Pharmacology with Small Data
This content is hosted by a third party. By showing the external content you accept the terms and conditions of vimeo.com.
Engineering Industry Day - Lyo-X
This content is hosted by a third party. By showing the external content you accept the terms and conditions of vimeo.com.